Clinical determinants of multiple drug failure in D2T RA 2000+ RA cohort 250+ refractory -Low financial status -Cancer Hx -CV comorbidities -Chronic use of NSAID or GCs Protective: Regular participation in leisure activities #POS0030 @RheumNow #EULAR2025 https://t.co/qNHQoHCb80

• https://x.com/AurelieRheumo/status/1932801565401784443/photo/1
• https://x.com/AurelieRheumo/status/1932801565401784443/photo/1

REGULATE-RA and REGULATE-HS FIH CAR-Treg targeting Cit-P Refractory RA (at least 3 MoA) 3 RA pts dosed & 3 Hidradenitis Suppurativa 0 SAE, DLTs or CRS Grade 1 TEAs mainly, one Grade 2 Efficacy and PD analysis ongoing #POS0034 #EULAR2025 @RheumNow https://t.co/Glw3NNFepF

• https://x.com/AurelieRheumo/status/1932806933473345695/photo/1
• https://x.com/AurelieRheumo/status/1932806933473345695/photo/1

If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1

• https://x.com/drdavidliew/status/1932807087840457182/photo/1

In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs. @RheumNow #EULAR2025 #OP0033 https://t.co/KkF9xFY4Cn

• https://x.com/DrMiniDey/status/1932808288434876508/photo/1

First line TNFi in RA in 140+ pts vs Standard of Care At 5 yrs outcome OR drug free remission 2.2 But no longer significant at 10yrs OR sustained remission 10yrs 1.91 OR single bioDMARDs 10yrs 2.64 Less 1% D2T #Poster0027 #EULAR2025 @RheumNow https://t.co/sL2XCbxPbl

• https://x.com/AurelieRheumo/status/1932809205779738869/photo/1

Access inequity across Europe is real. New #RheumaFacts data show major gaps in RMD care: 🔹 Full tsDMARD access in just 4% of countries 🔹 Self-referral possible in 57% 🔹 Rheum physio reimbursed in 63% 🔹 Psych care? Only 30%. Abstract#OP0025 @RheumNow #EULAR2025

🎩REGENCY: Obinutuzumab + standard therapy improved renal outcomes in #lupus nephritis across all tested response definitions (REGENCY, BLISS-LN, AURORA-1). Week 76 CRR consistently 13–16% higher vs placebo. Results hold despite variable thresholds. @RheumNow #EULAR2025 #OP0006

MONITOR-PsA (n=218): •36.5% had >1 csDMARD •Of those, 49.2% tried combination (combo) csDMARDs •63.6% of combo csDMARD users in MDA at 48wks •61.1% stopped due to side effects—not inefficacy Real-world support for csDMARD combos where biologics delayed. Abstract#OP0093 https://t.co/3Anme39VXk

• https://x.com/synovialjoints/status/1932820731923976498/photo/1

Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior to ADA for ACR20 (RR 1.28), HAQ-DI, VAS, but no difference in adverse events (RR 0.96) or DAS28-CRP improvement https://t.co/5mVY2Qvdms https://t.co/czxnlYHEAl

• Frontiers | Comparative effectiveness and safety of tofacitinib vs. adalimumab …

Ph 2 open label RCT TOFA in RA-ILD 52 wks 39pts 92% AE 8% 3 deaths FVC decline -69 ml No diff between UIP, NSIP or antifibrotic No control group #POS0619 #EULAR2025 @RheumNow https://t.co/3lqEUfObG9

• https://x.com/AurelieRheumo/status/1932812210629455966/photo/1

What’s worse for infection in GCA: tail end steroid taper, or a JAK inhibitor? This is exactly SELECT-GCA in the second 6mo. What happened? upa skews better on serious infection, worse on HZ JAKi might have infection risk, but not like steroids. OP0057 #EULAR2025 @RheumNow https://t.co/FigxviOW3e

• https://x.com/drdavidliew/status/1932812934737977387/photo/1

Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16

• https://x.com/JihaRheum/status/1932813824723505162/photo/1

Combination therapies in PsA not so far away: -Case series of 22 patients from large PsA cohort. -Combination therapy in PsA used when difficult to treat skin and msk involvement. -Deucravacitinib was the agent mostly used in combination with bDMARDs. -No major serious adverse https://t.co/YUyvuaJcsE

• https://x.com/AdelaCastro222/status/1932814725764518222/photo/1
• https://x.com/AdelaCastro222/status/1932814725764518222/photo/1
• https://x.com/AdelaCastro222/status/1932814725764518222/photo/1
• https://x.com/AdelaCastro222/status/1932814725764518222/photo/1

#OP0066 Danish registry study finds no increased risk of cancer recurrence with bDMARDs vs csDMARDs in RA patients with prior solid tumor in remission. IPTW-adjusted HR for any bDMARD: 0.92 (95% CI 0.38–2.21). 📉 TNFi, ,RTX also not associated with recurrence @RheumNow #EULAR2025

Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/Qg9HIwuslJ

• https://x.com/AurelieRheumo/status/1932815793399480685/photo/1